{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-062001","form_type":"8-K","ticker":"MRKR","cik":"0001094038","company_name":"Marker Therapeutics, Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.257517+00:00","generated_at":"2026-06-01T22:35:19.380973+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Marker Q1 net loss narrows to $2.4M; MT-601 shows durable CRs in APOLLO trial","bullets":["Net loss of $2.4M in Q1 2024 vs $4.9M in Q1 2023; cash $11.3M expected to fund into Q4 2025.","Three patients treated with MT-601: 2 complete responses (one >9 months after CAR-T relapse) and 1 partial response; well tolerated.","MT-601 received nonproprietary name 'neldaleucel' from USAN/INN; more data expected H2 2024.","MT-401-OTS IND cleared for AML/MDS; clinical initiation expected H2 2024; secured $2M NIH SBIR funding.","R&D expenses $2.6M, G&A $1.2M, both down YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-062001","json":"https://secwatch.observer/filing/0001104659-24-062001.json","markdown":"https://secwatch.observer/filing/0001104659-24-062001.md","text":"https://secwatch.observer/filing/0001104659-24-062001.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1094038/000110465924062001/0001104659-24-062001-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1094038/000110465924062001/tm2414438d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T22:35:19.380973+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"13bd3e73398a1122b8ce42fc936f5936e1527439","claim":"Marker Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today reported corporate updates and financial results for the first quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1094038/000110465924062001/0001104659-24-062001-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}